BridgeBio Pharma ( (BBIO) ) has shared an announcement.
On March 17, 2025, BridgeBio Pharma announced the departure of its Chief Financial Officer, Brian C. Stephenson, who will transition to a consulting role until March 2026. Thomas Trimarchi, Ph.D., has been appointed as the new President and CFO, a move that positions the company to continue its focus on genetic diseases and potentially enhance its operational strategies.
More about BridgeBio Pharma
BridgeBio Pharma, Inc. is a biopharmaceutical company focused on discovering, creating, testing, and delivering transformative medicines to treat genetic diseases. Founded in 2015, the company has a pipeline of development programs ranging from early science to advanced clinical trials, with a commitment to applying advances in genetic medicine to help patients swiftly.
YTD Price Performance: 16.91%
Average Trading Volume: 2,960,206
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $6.27B
For detailed information about BBIO stock, go to TipRanks’ Stock Analysis page.